Acute megakaryoblastic leukemia associated with mosaic Down's syndrome.
There have been several reports of the association between Down's Syndrome and acute megakaryoblastic (M7) leukemia (AMKL). The diagnosis of this rare form of leukemia has been better delineated by the use of the platelet peroxidase reaction and the antifactor VIII antibody immunoperoxidase test. In the past, the prognosis of patients with a combination of Down's Syndrome and AMKL has been extremely poor, with a median survival of 6.9 months for 11 reported cases in the literature. The present report reviews the previously reported cases and describes a unique patient with mosaic Down's syndrome and AMKL with favorable response to therapy.
D000677:Amsacrine / Q000008:administration & dosage; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use; D002886:Chromosomes, Human, Pair 17; D002999:Clone Cells / Q000473:pathology; D003520:Cyclophosphamide / Q000008:administration & dosage; D003561:Cytarabine / Q000008:administration & dosage; D004314:Down Syndrome / Q000150:complications* / Q000235:genetics; D004317:Doxorubicin / Q000008:administration & dosage; D005047:Etoposide / Q000008:administration & dosage; D005260:Female; D006801:Humans; D006854:Hydrocortisone / Q000008:administration & dosage; D007223:Infant; D007947:Leukemia, Megakaryoblastic, Acute / Q000150:complications* / Q000188:drug therapy / Q000235:genetics; D008727:Methotrexate / Q000008:administration & dosage; D009030:Mosaicism; D011241:Prednisone / Q000008:administration & dosage; D013866:Thioguanine / Q000008:administration & dosage; D014314:Trisomy
D000677:Amsacrine; D003561:Cytarabine; D005047:Etoposide; D004317:Doxorubicin; D003520:Cyclophosphamide; D013866:Thioguanine; D011241:Prednisone; D006854:Hydrocortisone; D008727:Methotrexate